For the year ending 2025-12-31, CPIX made $44,521,431 in revenue. -$2,836,128 in net income. Net profit margin of -6.37%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Net revenues | 44,521,431 | 37,867,945 | ||
| Cost of products sold | 6,667,207 | 6,585,972 | ||
| Selling and marketing | 19,098,153 | 17,023,023 | ||
| Research and development | 5,566,498 | 4,816,206 | ||
| General and administrative | 11,946,909 | 11,126,901 | ||
| Amortization and impairment | 4,034,657 | 4,748,252 | ||
| Total costs and expenses | 47,313,424 | 44,300,354 | ||
| Operating loss | -2,791,993 | -6,432,409 | ||
| Interest income | 476,748 | 334,444 | ||
| Other income - gain on insurance proceeds | 0 | 237,089 | ||
| Interest expense | 495,990 | 605,508 | ||
| Loss before income taxes | -2,811,235 | -6,466,384 | ||
| Income tax (expense) benefit | 40,256 | -22,669 | ||
| Equity in loss of investee | -13,220 | - | ||
| Net loss | -2,864,711 | -6,443,715 | ||
| Net (income) loss at subsidiary attributable to noncontrolling interests | -28,583 | 36,055 | ||
| Net loss attributable to common shareholders | -2,836,128 | -6,479,770 | ||
| Basic EPS | -0.19 | -0.46 | ||
| Diluted EPS | -0.19 | -0.46 | ||
| Basic Average Shares | 14,854,619 | 14,060,272 | ||
| Diluted Average Shares | 14,854,619 | 14,060,272 | ||
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)